Jacobs Levy Equity Management
TCRX icon

Jacobs Levy Equity Management’s TScan Therapeutics TCRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$816K Buy
808,356
+620,204
+330% +$663K ﹤0.01% 747
2025
Q4 		$188K Buy
+188,152
New +$272K ﹤0.01% 887
2025
Q1 		– Sell
-18,951
Closed -$57.6K – 1197
2024
Q4 		$57.6K Sell
18,951
-84,489
-82% -$383K ﹤0.01% 922
2024
Q3 		$515K Buy
+103,440
New +$624K ﹤0.01% 828

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Jacobs Levy Equity Management's TCRX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its TScan Therapeutics (TCRX) stake by 330% in Q1 2026, buying an estimated $663K and bringing the position to 808,356 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Jacobs Levy Equity Management first reported a position in TCRX in Q3 2024 and has held it in 4 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Jacobs Levy Equity Management held 808,356 shares of TScan Therapeutics worth $816K as of Q1 2026.
  • Jacobs Levy Equity Management bought 620,204 TScan Therapeutics shares in Q1 2026, an estimated $663K.
  • TScan Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #747 holding.
  • Jacobs Levy Equity Management first reported a position in TScan Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.